QualityDipStocks / Health Care · Life Sciences Tools
Mettler-Toledo International MTD
Not in a dip: trading near its 52-week high.
A quality company trading well above our fair value estimate, 13% over its Market Value.
- Fair value est.
- $678.88−59%
- Market Value
- $1,477price +13%
- Off 52-wk high
- −3%
- Risk vs market
- Below marketbeta 0.81
2 bullish · 5 bearish See why
Key levels
Every level vs today’s $1,675
- Fair value est.base case$678.88−59.5%
- 52-wk lowlowest close, 1 year$1,026−38.8%
- Market Valueavg paid since Jul 30$1,477−11.8%
- PriceFri Oct 30 close$1,675you are here
- 52-wk highhighest close, 1 year$1,719+2.6%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, MTD’s free cash flow would need to grow about 19% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much MTD moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 2.5× the S&P 500’s.
- Beta vs S&P 500
- 0.81
- Volatility
- 31% vs 13% SPY
- Correlation SPY
- 0.33
- Correlation QQQ
- 0.20
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 2 of 5
Cash returnsShare count down 2.8% in a year: $775M of buybacks over 12 months.
QualityPasses all four of our quality checks: cash generation, returns on capital, growth and balance sheet.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $678.88, 59% below the price.
ValuationP/E of 37.3× is 15% above its own average of 32.4× at the last 3 fiscal year-ends.
GrowthSales grew 0.9% a year over the last three fiscal years, below the 7.3% median for the 101 Health Care companies we cover.
ValuationPrice / book of 2633.9×, above the 5.2× median for the 93 Health Care companies we cover.
ValuationTrades 13.4% above its Market Value of $1,477, the average price paid since the Jul 30 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on Mettler-Toledo International in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Life Sciences Tools
All fundamentals
P/E 37.3 · FCF yield 2.6% · Sales +7%
Valuation
- P/E
- 37.3×3-yr-end avg 32.4× · Health Care median 29.2×
- Price / FCF
- 39.1×
- FCF yield
- 2.6%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 8.17×
- Price / book
- 2633.92×
- Market cap
- $33.8Bprice × diluted shares
- Enterprise value
- $35.8B
Growth
- Revenue, 12 months
- $4.1B
- Sales growth, 12 months
- +6.9%vs the 12 months before
- Sales growth, 3 yrs
- +0.9%/yrfrom FY2022
- Diluted EPS, 12 months
- $44.36
- EPS growth, last FY
- +3.9%
- Net income, 12 months
- $906M
- Net income growth
- +9%12 months vs before
Profitability
- Gross margin
- 60.3%
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- 21.9%
- FCF margin
- 20.9%
- Return on equity
- n/anot reported in its SEC filings
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $51M
- Total debt
- $2.0B
- Net cash
- −$2.0B
- Debt / equity
- n/an/m: equity near zero
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $864M
- FCF growth, 12 months
- +2%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $775M2.3% of market cap
- Share count, 1 year
- −2.8%diluted shares vs a year ago
- Stock-based comp
- $23M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Mettler-Toledo International’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $678.88 · MV $1,477 · FCF value $1,047
Assumes 3.0% growth for 5 years (revenue grew 0.9% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $42.84 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Jul 31, 2026. Net debt $2.0B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only arm once a company is in a dip.
Momentum & 52-week range
RSI 65 · 5 days +0.3%
The business
FCF $0.9B · Sales +4%
- Free cash flow, 12 months$0.9B
- Free-cash-flow yield2.5%
- Free-cash-flow margin21%
- Gross margin60%
- Operating margin28%
- Return on invested capital44%
- Sales growth (latest quarter vs year-ago quarter)+4%
- Net debt / EBITDA1.6×
Next report
Nov 5
- DateThu Nov 5, after the close
- Consensus EPS$12.11
- Year-ago EPS$11.15
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
Get a text when MTD fires a reversal signal
One text when a published rule fires on MTD or any of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.